Table 3.
Genome-wide association meta-analysis of ESRD case-only APOL1 × SNP interaction analysis
| Meta-Analysis (ESRD cases only, APOL1 risk is the outcome) | Non-diabetic ESRD case- control analysis |
LN-ESRD case- SLE control Analysis |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||||
| SNP | Chr | Position | Gene Region |
Minor Allele |
MAF WF non-diabetic ESRD cases APOL1 risk (N=803) |
MAF WF non- nephropathy controls APOL1 non- risk (N=148) |
MAF LN-ESRD cases APOL1 risk (N=223) |
MAF SLE non- nephropathy controls APOL1 non-risk (N=55) |
Meta P-value |
OR (95% CI) |
OR non- diabetic ESRD |
OR LN- ESRD |
OR APOL1 Risk |
OR APOL1 Non-Risk |
OR APOL1 Risk |
OR APOL1 Non- Risk |
| rs7660268 d | 4p15 | 14349700 | near LINC01085 | A | 0.15 | 0.10 | 0.14 | 0.12 | 2.10 ×10−7 | 1.63 (1.32–2.00) | 1.91 | 1.31 | 1.49 | 0.73 | 1.08 | 0.83 |
| rs75167652 d | 6q26 | 161091168 | near LPA, PLG | G | 0.04 | 0.02 | 0.05 | 0.02 | 1.70 ×10−6 | 2.70 (1.81–4.04) | 2.13 | 3.75 | 3.82 | 0.66 | 2.01 | 0.84 |
| rs79741405 i, d | 6q26 | 161094269 | near LPA, PLG | T | 0.05 | 0.02 | 0.05 | 0.02 | 7.70 ×10−8 | 2.97 (2.01–4.39) | 2.25 | 4.34 | 1.96 | 0.89 | 2.86 | 0.95 |
| rs1551122a | 12q21 | 80765800 | OTOGL | G | 0.19 | 0.15 | 0.21 | 0.17 | 8.61 ×10−7 | 1.49 (1.27–1.76) | 1.46 | 1.54 | 1.59 | 0.73 | 0.92 | 1.11 |
i – imputed SNP in MegaChip cohort (all SNPs are imputed in the LN-ESRD cohort)
d or r – dominant, or recessive model; if not noted, additive model was used
Abbreviations: MAF minor allele frequency; WF Wake Forest; LN lupus nephritis; SLE systemic lupus erythematosus; OR odds ratio; CI confidence interval